© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
December 28, 2017
April 19, 2013
We estimated the long-term risks and benefits of disease modifying therapies. Benefits were favored by natalizumab with minimal increased risks in the negative anti-JC virus population.
October 11, 2011
Even small changes in average copayment for long-term controller asthma medications can result in significant reductions in medication use and increases in healthcare services.
April 08, 2011